Triamcinolone aminobenzal benzamidoisobutyrate (TBI-PAB; brand name Taucorten) is a synthetic glucocorticoid corticosteroid which is no longer marketed.[1][2]
Clinical data | |
---|---|
Trade names | Taucorten |
Other names | TBI-PAB; TBI/PAB; Tbi-Pab; 16α,17α-(4-Dimethylamino- benzyliden)triamcinolone 21-(β-benzoylamino)isobutyrate; 21-(3-(benzoylamino)-2-methyl-1-oxopropoxy)-16α,17α-(((4-(dimethylamino)phenyl)- methylene)bis(oxy))-9α-fluoro-11β-hydroxypregna-1,4-diene-3,20-dione |
Drug class | Corticosteroid; Glucocorticoid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C41H47FN2O8 |
Molar mass | 714.831 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1228–. ISBN 978-1-4757-2085-3.
- ^ Martindale W, Royal Pharmaceutical Society of Great Britain. Dept. of Pharmaceutical Sciences (1993). The Extra Pharmacopoeia. Pharmaceutical Press. p. 740. ISBN 978-0-85369-300-0.